Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABUS

ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

2.88USD-0.04 (-1.37%)Market Closed
Watchlist

Market Summary

USD2.88-0.04
Market Closed
-1.37%

ABUS Stock Price

View Fullscreen

ABUS RSI Chart

ABUS Valuation

Market Cap

483.0M

Price/Earnings (Trailing)

-6.4

Price/Sales (Trailing)

21.71

EV/EBITDA

-6.68

Price/Free Cashflow

-5.57

ABUS Price/Sales (Trailing)

ABUS Profitability

EBT Margin

-323.58%

Return on Equity

-63.24%

Return on Assets

-47.57%

Free Cashflow Yield

-17.97%

ABUS Fundamentals

ABUS Revenue

Revenue (TTM)

22.2M

Rev. Growth (Yr)

-21.74%

Rev. Growth (Qtr)

0.15%

ABUS Earnings

Earnings (TTM)

-75.5M

Earnings Growth (Yr)

-14.44%

Earnings Growth (Qtr)

-17.61%

Breaking Down ABUS Revenue

Last 7 days

5.1%

Last 30 days

25.5%

Last 90 days

55.9%

Trailing 12 Months

7.8%

How does ABUS drawdown profile look like?

ABUS Financial Health

Current Ratio

6.34

ABUS Investor Care

Shares Dilution (1Y)

7.18%

Diluted EPS (TTM)

-0.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202333.1M23.5M22.2M0
202221.5M33.4M36.0M39.0M
20217.5M8.4M10.2M11.0M
20206.2M6.5M6.7M6.9M
20195.2M4.6M9.5M6.0M
201811.9M12.1M6.8M5.9M
20173.8M6.1M8.4M10.7M
201619.0M13.2M7.3M1.5M
201515.2M16.8M16.5M24.9M
201417.8M16.7M18.1M15.0M
201317.9M17.1M16.3M15.5M
201217.1M17.5M17.9M18.3M
201120.2M19.0M17.8M16.6M
201016.2M17.9M19.6M21.4M
200900014.4M

Tracking the Latest Insider Buys and Sells of Arbutus Biopharma Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 02, 2024
sims karen
sold
-10,077
2.3125
-4,358
chief medical officer
Feb 02, 2024
mcelhaugh michael j.
sold
-23,504
2.3125
-10,164
interim president & ceo
Feb 02, 2024
sofia michael j.
sold
-23,083
2.3125
-9,982
chief scientific officer
Feb 02, 2024
hastings david c
sold
-22,183
2.3125
-9,593
chief financial officer
Feb 01, 2024
sims karen
acquired
-
-
101,000
chief medical officer
Feb 01, 2024
mcelhaugh michael j.
acquired
-
-
123,800
interim president & ceo
Feb 01, 2024
sofia michael j.
acquired
-
-
109,500
chief scientific officer
Feb 01, 2024
naftzger j. christopher
acquired
-
-
95,100
general counsel and cco
Feb 01, 2024
hastings david c
acquired
-
-
112,500
chief financial officer
Feb 01, 2023
collier william h.
acquired
-
-
216,500
president and ceo

1–10 of 19

Which funds bought or sold ABUS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 26, 2024
Virtu Financial LLC
new
-
45,000
45,000
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
11.24
20,000
75,000
-%
Feb 15, 2024
Front Row Advisors LLC
unchanged
-
4,935
26,250
0.01%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
5,786
30,771
-%
Feb 15, 2024
GTS SECURITIES LLC
new
-
78,600
78,600
-%
Feb 15, 2024
Virtus ETF Advisers LLC
sold off
-100
-81,281
-
-%
Feb 15, 2024
DAGCO, INC.
new
-
15,750
15,750
0.01%
Feb 15, 2024
MONETA GROUP INVESTMENT ADVISORS LLC
added
8.7
15,810
62,500
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
241,272
241,272
-%
Feb 15, 2024
BARCLAYS PLC
added
63.79
272,000
540,000
-%

1–10 of 40

Are Funds Buying or Selling ABUS?

Are funds buying ABUS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABUS
No. of Funds

Unveiling Arbutus Biopharma Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
two seas capital lp
5.4%
9,041,927
SC 13G/A
Feb 14, 2024
whitefort capital management, lp
7.9%
13,197,062
SC 13G/A
Feb 12, 2024
blackrock inc.
6.2%
10,390,300
SC 13G/A
Nov 21, 2023
two seas capital lp
5.7%
9,503,103
SC 13G
Sep 11, 2023
whitefort capital management, lp
6.0%
10,013,899
SC 13G
Feb 03, 2023
blackrock inc.
5.6%
8,700,392
SC 13G
Feb 14, 2022
rtw investments, lp
1.7%
2,504,493
SC 13G/A
Oct 20, 2021
roivant sciences ltd.
29.1%
38,847,462
SC 13D/A
Feb 16, 2021
foresite capital fund iv, l.p.
0%
0
SC 13G/A
Feb 12, 2021
rtw investments, lp
7.05%
5,978,355
SC 13G/A

Recent SEC filings of Arbutus Biopharma Corp

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Jan 08, 2024
8-K
Current Report
Jan 04, 2024
8-K
Current Report

Peers (Alternatives to Arbutus Biopharma Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
4.1B
726.4M
-12.60% 32.37%
-66.62
5.62
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
SMALL-CAP
1.5B
398.2M
-3.38% -9.50%
21.06
3.78
85.90% -14.05%
738.0M
983.7M
-9.17% -57.89%
-1.35
0.75
-50.36% 17.16%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Arbutus Biopharma Corp News

Latest updates
AmericanBankingNEWS72 minutes ago
InvestorsObserver09 Feb 202408:00 am

Arbutus Biopharma Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue0.2%4,658,0004,651,0006,687,0006,245,0005,952,00014,241,00012,581,0003,206,0003,340,0002,329,0002,113,0002,386,0001,523,0001,514,0001,491,0003,988,5006,486,000653,000679,0001,678,0001,587,000
Operating Expenses13.8%26,216,00023,036,00024,100,00028,807,00023,763,00028,350,00023,555,00024,002,00021,748,00020,971,00017,789,00018,687,00016,740,00014,655,00014,638,00014,653,00094,086,00021,298,00019,875,00018,581,00034,013,000
  S&GA Expenses-2.3%5,842,0005,980,0005,552,0004,249,0003,493,0005,200,0004,892,0004,597,0004,183,0004,478,0003,878,0003,661,0004,065,0003,566,0003,553,0001,877,0003,249,0008,189,0004,412,0005,927,0002,631,000
  R&D Expenses14.0%20,169,00017,692,00018,275,00022,949,00020,055,00022,942,00018,462,00019,212,00016,709,00015,799,00013,782,00016,392,00012,065,00010,465,00010,416,00012,418,00017,731,00012,740,00014,712,00011,063,00016,566,000
EBITDA Margin-6.4%-3.14-2.96-2.09-1.76-1.90-2.04-3.15-6.13-6.60-7.94-8.04-8.35---------
Interest Expenses-73.1%46,000171,000198,000309,000429,000482,000506,000560,000762,000763,000772,000797,0001,074,0001,099,0001,041,000994,0001,100,0002,00012,000122,000-
Income Taxes-------4,444,000----------12,656,000----4,282,000
Earnings Before Taxes-17.6%-20,104,000-17,094,000-16,339,000--17,567,000-14,192,000-11,321,000--19,158,000-19,387,000-16,381,000-17,042,000-18,755,000-14,087,000-13,861,000-24,654,000-95,159,000-23,315,000-23,251,000-18,249,000-28,755,000
EBT Margin-5.8%-3.24-3.06-2.17-1.84-2.00-2.16-3.35-6.55-7.08-8.57-8.79-9.22---------
Net Income-17.6%-20,104,000-17,094,000-16,339,000-21,932,000-17,567,000-14,192,000-15,765,000-21,321,000-19,158,000-19,387,000-16,381,000-17,042,000-18,755,000-14,087,000-13,861,000-24,654,000-82,503,000-23,315,000-23,251,000-18,249,000-24,473,000
Net Income Margin-9.5%-3.39-3.10-2.11-1.78-1.91-2.11-3.52-6.94-7.08-8.57-8.79-9.22---------
Free Cashflow-6.8%-21,816,000-20,418,000-27,418,000-17,124,000-18,783,000-20,505,00020,544,000-19,664,000-16,056,000-14,641,000-17,980,000-15,165,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-10.3%15917719119520421623720416613514613713198.00103106117193209228245
  Current Assets-10.8%14215915315114115817316112783.0013712812186.0088.0094.0094.00100112129144
    Cash Equivalents-35.5%18.0027.0041.0031.0024.0047.0081.0010978.0031.0079.0052.0097.0046.0026.0032.0090.0079.0084.0037.0022.00
  Net PPE-6.3%5.005.005.005.005.005.006.006.006.007.007.007.007.008.008.009.009.009.0010.0010.0010.00
  Goodwill------------------22.0022.0022.0022.00
Liabilities-6.7%39.0042.0047.0059.0058.0063.0071.0035.0035.0035.0032.0035.0034.0032.0029.0033.0034.0028.0028.0028.0030.00
  Current Liabilities-9.0%22.0025.0025.0033.0028.0030.0032.0011.0010.009.007.0010.008.006.004.008.009.009.009.0011.0013.00
Shareholder's Equity-11.4%11913514413714615316616913010111410297.0066.0073.0073.0084.00164181200215
  Retained Earnings-1.6%-1,257-1,237-1,220-1,203-1,181-1,164-1,150-1,134-1,112-1,088-1,065-1,045-1,025-1,004-986-970-942-857-831-805-784
  Additional Paid-In Capital3.0%80.0077.0074.0072.0071.0069.0067.0065.0064.0064.0062.0061.0060.0058.0057.0055.0055.0054.0050.0048.0046.00
Accumulated Depreciation0.6%12.0011.0011.0011.0010.0010.0010.009.009.008.008.008.007.007.009.006.009.008.007.007.006.00
Shares Outstanding0.5%16816716515715114914814597.0097.0093.0090.00---------
Float------290---238---130---118---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-11.4%-21,784-19,559-27,301-16,990-18,692-20,29320,619-19,606-16,036-14,009-17,881-15,013-12,174-8,801-15,453-13,351-23,470-17,605-16,580-17,074-13,204
  Share Based Compensation-16.2%2,4832,9642,1311,6671,7152,0641,7361,4311,6151,7431,6351,4311,6881,5971,445-23.001,5163,7841,5227971,828
Cashflow From Investing623.7%10,4291,44116,67812,682-13,738-13,830-60,056-8,12115,969-38,74718,221-49,97614,09723,371-2,401-58,82216,1559,97261,03338,48324,378
Cashflow From Financing-64.6%1,6814,74220,41711,0849,13211311,48559,12146,9524,28926,87420,21049,0964,95912,48113,89318,5492,4792,536109435

ABUS Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue    
Revenues$ 4,658$ 5,952$ 15,996$ 32,774
Operating expenses    
Research and development20,16920,05556,13661,459
General and administrative5,8423,49317,37413,585
Change in fair value of contingent consideration205215(158)624
Total operating expenses26,21623,76373,35275,668
Loss from operations(21,558)(17,811)(57,356)(42,894)
Interest income1,4946944,2231,249
Interest expense(46)(429)(415)(1,417)
Foreign exchange (gain) loss6(21)11(18)
Total other income (loss)1,4542443,819(186)
Loss before income taxes(20,104)(17,567)(53,537)(43,080)
Income tax expense000(4,444)
Net loss$ (20,104)$ (17,567)$ (53,537)$ (47,524)
Loss per share    
Basic (in USD per share)$ (0.12)$ (0.12)$ (0.32) 
Diluted (in USD per share)$ (0.12)$ (0.12)$ (0.32)$ (0.32)
Weighted average number of common shares    
Basic (in shares)167,512,708150,995,191165,085,243 
Diluted (in shares)167,512,708150,995,191165,085,243149,385,999
Comprehensive loss    
Unrealized gain (loss) on available-for-sale securities$ 584$ (907)$ 1,604$ (2,669)
Comprehensive loss(19,520)(18,474)(51,933)(50,193)
Collaborations and licenses    
Revenue    
Revenues3,9353,60713,32927,381
Non-cash royalty revenue    
Revenue    
Revenues$ 723$ 2,345$ 2,667$ 5,393

ABUS Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 17,531$ 30,776
Investments in marketable short-term securities116,649116,137
Accounts receivable2,1711,352
Prepaid expenses and other current assets5,2562,874
Total current assets141,607151,139
Property and equipment, net of accumulated depreciation of $11,541 (December 31, 2022: $10,801)5,0335,070
Investments in marketable securities, non-current10,49637,363
Right of use asset1,5021,744
Other non-current assets3103
Total assets158,641195,419
Current liabilities:  
Accounts payable and accrued liabilities9,80616,029
Deferred license revenue, current12,10616,456
Lease liability, current412372
Total current liabilities22,32432,857
Liability related to sale of future royalties8,11010,365
Contingent consideration7,3737,531
Deferred license revenue, non-current05,999
Lease liability, non-current1,4971,815
Total liabilities39,30458,567
Stockholders’ equity  
Issued and outstanding: 167,695,247 (December 31, 2022: 157,455,363)1,346,0151,318,737
Additional paid-in capital79,54672,406
Deficit(1,257,340)(1,203,803)
Accumulated other comprehensive loss(48,884)(50,488)
Total stockholders’ equity119,337136,852
Total liabilities and stockholders’ equity$ 158,641$ 195,419
ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
 CEO
 WEBSITEwww.arbutusbio.com
 EMPLOYEES96

Arbutus Biopharma Corp Frequently Asked Questions


What is the ticker symbol for Arbutus Biopharma Corp? What does ABUS stand for in stocks?

ABUS is the stock ticker symbol of Arbutus Biopharma Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arbutus Biopharma Corp (ABUS)?

As of Wed Feb 28 2024, market cap of Arbutus Biopharma Corp is 482.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers. The fair value of Arbutus Biopharma Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arbutus Biopharma Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arbutus Biopharma Corp a good stock to buy?

The fair value guage provides a quick view whether ABUS is over valued or under valued. Whether Arbutus Biopharma Corp is cheap or expensive depends on the assumptions which impact Arbutus Biopharma Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABUS.

What is Arbutus Biopharma Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 28 2024, ABUS's PE ratio (Price to Earnings) is -6.4 and Price to Sales (PS) ratio is 21.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABUS PE ratio will change depending on the future growth rate expectations of investors.